IDEX Corporation Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 saw 5% organic sales growth, 28% order growth, and 12% higher adjusted EPS, driven by strong demand in HST, especially in data centers, semiconductors, and space/defense. Raised full-year guidance for organic growth, margins, and EPS, with robust backlog and ongoing investments supporting future expansion.
-
Management highlighted strong performance in HST, especially in data centers, semiconductors, and space/defense, with FMT and FSD showing mixed trends. Capital deployment will focus on share repurchases and targeted bolt-on M&A, while integrated platforms and advanced technologies are expected to drive durable growth through 2027.
-
The meeting covered director elections, executive compensation, and auditor ratification, all of which passed with strong shareholder representation. No questions or comments were raised by stockholders during the meeting.
-
Q1 2026 saw 5% organic sales growth and 10% order growth, led by HST's strong performance. Full-year guidance was raised, with robust backlog and continued capital deployment supporting growth, while macro uncertainty keeps FMT and FSDP outlooks conservative.
-
Phase three is at its midpoint, with strong HST growth, ongoing M&A, and a focus on digital and AI transformation. Capital deployment balances bolt-on acquisitions and share repurchases, while global expansion leverages localized operations. HST leads growth, FMT and FSDP remain stable, and innovation is driven by applying core technologies to new markets.
Fiscal Year 2025
-
Q4 2025 saw organic sales and margin growth, led by HST's strong order momentum in data centers and semiconductors. 2026 guidance calls for 1%-2% organic growth, margin expansion, and continued capital deployment to M&A and share repurchases, with HST expected to outperform other segments.
-
Q3 2025 results exceeded expectations with 5% organic revenue growth and strong HST performance. Adjusted EBITDA margin expanded, and robust cash flow enabled $75M in share repurchases. Full-year guidance was narrowed, with continued focus on bolt-on M&A and capital returns.
-
Q2 2025 saw strong adjusted EBITDA margin and EPS, but macro volatility and delayed large orders led to reduced full-year guidance. Healthy demand in pharma, energy, and data centers offset weakness in semiconductors and auto. Capital deployment remains balanced, with continued focus on M&A and shareholder returns.
-
Q1 2025 results exceeded expectations with record orders and strong performance in key markets, despite a 1% organic sales decline. Full-year guidance is maintained, with proactive cost savings and price actions set to offset tariff impacts and potential volume pressures.
Fiscal Year 2024
-
Delivered strong Q4 results with organic orders growth and margin expansion, despite macro uncertainty. 2025 guidance anticipates 1%-3% organic growth, margin improvement, and EPS growth, led by HST and supported by Mott integration and platform optimization.
-
Q3 delivered stable order rates, strong free cash flow, and margin expansion in key segments. HST orders surged, Mott integration advanced, and guidance for Q4 and full year remains steady despite macro uncertainty and delayed semiconductor recovery.
-
Q2 results met expectations with stable core demand but project delays due to macro and political uncertainty. Guidance was lowered for 2024, reflecting delayed recovery in HST and FSDP, while FMT remains resilient. Recent acquisitions and innovation support long-term growth.
-
The acquisition targets a leader in precision filtration, expanding access to high-growth markets and leveraging complementary expertise. The $1B deal is expected to be accretive to EPS by 2026, with significant margin expansion and synergies anticipated through operational excellence and integration.